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Geriatric assessment is a requirement to effectively 
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Most European countries are currently faced by a major 
demographic shift that will see increasing numbers of older 
patients. This represents a corresponding increase in the 
number of older patients presenting for radiation therapy. It 
is recognised that this will require “age attuning” of our 
cancer treatment services to provide a more holistic 
approach to the care of older patients. Comprehensive 
Geriatric Assessment (CGA) or Geriatric Assessment (GA) as 
used in the oncology literature, can identify risk factors for 
adverse outcomes in older cancer patients. CGA was designed 
to more accurately detect frailty in older patients, and both 
the National Comprehensive Cancer Network (NCCN) and 
International Society of Geriatric Oncology (SIOG) 
recommend its use in Oncology. CGA includes a compilation 
of reliable and valid tools to assess geriatric domains such as 
comorbidity, functional status, physical performance, 
cognitive status, psychological status, nutritional status, 
medication review, and social support. The benefits of CGA 
include greater diagnostic accuracy, reduced hospitalisation 
and improved survival and quality of life. Benefits for cancer 
patients include predicting complications of treatment, 
estimating survival and detection of problems not found using 
standard oncology performance measures, such as 
performance status. Cancer treatment is a physiologic 
stressor, and its impact on older patients is poorly defined in 
relation to baseline reserve capacity. GA provides a means of 
quantifying known heterogeneity in older patients, and may 
identify problems that could potentially be reversed, or 
better managed, in order to improve outcomes. Despite the 
evidence demonstrating the benefits of GA in improving the 
health status of older patients, its adoption in (radiation) 
oncology has not been widespread. The published literature 
lacks a standardised approach to GA in Oncology, making 
interpretation of the current evidence difficult. Exacerbating 
this issue is the traditional exclusion of older patients from 
clinical trials. GA has the potential to predict toxicity, 
survival and quality of life in older patients, and further 
research is needed to clarify its role. GA is known to be time 
and resource intensive, and recent studies have sought to 
develop shorter screening tools specifically for oncology 
patients, such as the G8. However, none of these approaches 
have been validated to date, with one obvious drawback 
being the lack of comparison in the form of a “gold standard” 
comprehensive approach. One potential solution to resource 
and time issues is the sharing of responsibility among the 
multidisciplinary team, with radiation therapists having a 
valuable role to play as front line staff. Recent focus in policy 
documents on measures to improve the quality of healthcare 
for older patients has resulted in a need to adequately 
prepare qualified health professionals to work together in a 
more collaborative manner. Many international models of 
Geriatric Oncology exist, however implementation is 
institution-specific and must take account of existing 
resources and infrastructure. In addition, there is currently 
no formal Geriatric Oncology fellowship scheme in most 
countries (apart from the US) or education programme in 
place for oncology professionals on how to best implement 
geriatric assessment. Many healthcare professionals, do not 
receive any training in the fundamental principles of geriatric 
medicine and how they may apply to their profession. The 
aim of this presentation is to present a critical overview of 
the current literature on GA in radiation oncology, and 
previous research by the authors in this field. It will also 
incorporate aspects of feasibility and requirements for a 
geriatric oncology service. The latter will include educational 
aspects and the need for adapted curricula in radiation 
oncology to incorporate aspects of aging, optimal treatment 
and attitudes towards aging. 
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Treatment choices in the elderly: focus on breast cancer 
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· The evidence for treatment ofolder patients with breast 
cancer is scarce due to lack of clinical trials andselective 
inclusion of patients 
· Older patients are less willing totrade quality of life for 
absolute survival gain, but data that can providepatients with 
information concerning these outcomes are lacking 
· The recently performed “FOCUS onChoice” study has shown 
that older patients choose a mastectomy more 
frequentlythan younger patients  
· Recent trials suggest thatradiotherapy can be omitted in 
older patients with low-risk tumours 
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What is the Young ESTRO Committee and what can it do for 
young radiation oncology professionnals? 
J.E. Bibault
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Department, Paris, France 
1 
 
The Young Task Force 
The first YTF was formed in 2011 at the Anniversary 
congressbased on the decision of the ESTRO Steering 
Committee of 16 June 2009. At thebeginning, members of the 
YTF were appointed by the Board each year. In 2012,at the 
Agorá meeting, YTF members’ term was changed to three 
years, renewableonce. This meeting allowed for “strategic 
discussions”, bringing young,promising RT scientists / 
professionals together with the core ESTROleadership. The 
Agorá meeting provided valuable input for the YTF. Several 
projectsrealised by the YTF were based on the results of the 
Agorá meeting. 
The first chair of the YTF, Daniel Zips, thought that theaim of 
the YTF, from the start, was to become a committee and be 
an integralpart of ESTRO governance contributing to 
activities and supporting the youngmembers. The Young task 
force (YTF) is a key structure in securing thelong-term future 
of ESTRO. The 3rd YTF succeeded in initiating several 
projects(e.g. revision of YTF structure, involvement in ESTRO 
committees, improvementof online communication, etc.). To 
carry on these essential activities, the YTFwas changed to 
become a full ESTRO Committee in 2015. 
Composition of the Young Committee 
The Young Committee reflects the diversity 
andmultidisciplinarity of ESTRO with members from clinical 
radiation oncology,radiobiology, physics and RTTs. Each 
member also acts as an observer in one ofthe other standing 
committee of ESTRO: 
• Jean-Emmanuel Bibault (Paris, France): National Societies 
Committee 
• Gerben Borst (Amsterdam, The Netherlands) : Clinical 
Committee 
• Laura Mullaney (Dublin, Ireland): RTT Committee 
• Kasper Rouschop (Maastricht, The Netherlands): 
Radiobiology Committee 
• Maximilian Schmid (Vienna, Austria): GEC-ESTRO 
Brachytherapy Committee 
